NCT07756281RecruitingPhase 1
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 9 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Jun 2029
- Lead sponsor
- ParVation Therapeutics, Inc.
- Diseases
- Pancreatic cancer
- NCT number
- NCT07756281
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 40
- From 1 Sept 2026 to the primary completion date, 1 Jun 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions).
Other illness
- Serious heart, lung, liver, or other medical problems that would make study treatment unsafe.
- Active, uncontrolled infections.
- Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated).
- Known brain or nervous system involvement from the cancer that is not stable or controlled.
Other
- Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.
Who the study is looking for
- Adults (18 years and older).
- Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
- Cancer confirmed by tissue or cell examination (histology or cytology).
- At least one measurable tumor on scans.
- Good enough general health and organ function to receive study treatment, as judged by the study doctor.
- Able to swallow oral medicines.
- Willing to follow study visit schedule and contraception requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD Anderson Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.